Figure 2. Survival rates after early treatment with 10 mg/kg free or nSSL-encapsulated MPS (upper graph) or BMS (lower graph).

Representative results for ICR mice infected with PbA are presented. Arrows denote treatment administration. ECM prevention is reflected in longer survival times, due to the development of severe anemic malaria, and as a result creation of a survival time-window for anti-plasmodial administration. Significant differences in survival were seen between non-treated and nSSL-MPS-treated groups (p = 0.01) and between non-treated mice and mice administered free or nSSL-BMS (p<0.01).